Can We Trust AI in a GxP-Regulated Environment? Validation, Explainability, and Human Oversight
“It’s a black box – Quality will never accept it”. I hear this in almost every pharma conversation about AI. It’s a legitimate concern, but the answer is more nuanced, and more actionable – than the objection suggests.
The starting point: regulated industries have always validated systems whose internals are complex. What validation actually requires is not that every internal mechanism be humanly readable, but that the system’s behavior be specified, tested, documented, and controlled. The question shifts from “can I read the logic?” to “can I demonstrate, with evidence, that the system performs its intended use reliably – and detect when it stops doing so?”
For AI systems, this translates into a set of concrete pillars:
- Data governance. The training, validation, and test datasets are part of the validated system. Their provenance, labeling process, and representativeness of production conditions must be documented and versioned. Change the dataset, and you have changed the system.
- Statistical performance qualification. Instead of deterministic test scripts, you define acceptance criteria on held-out data: detection rate, false-reject rate, confidence distributions – with predefined thresholds and challenge sets including known difficult cases.
- Explainability, proportionate to risk. Full mechanistic transparency is rarely achievable with deep learning, but useful explainability is: heatmaps showing where in the image the model saw the defect, feature importance for tabular models, confidence scores that route uncertain cases to humans. Regulators increasingly ask for appropriate explainability, not total transparency.
- Human oversight by design. The most robust pattern in GxP contexts is AI as a decision-support layer with defined autonomy boundaries: the model handles clear cases; borderline cases go to qualified humans; every decision is auditable. Autonomy can expand gradually as evidence accumulates.
- Change control for the model lifecycle. Retraining is a change. It needs triggers, impact assessment, revalidation criteria, and rollback capability – exactly the discipline pharma already excels at, applied to a new object.
The regulatory landscape – from EU AI Act obligations to evolving GMP guidance on AI – is converging on this same philosophy: risk-based, evidence-driven, lifecycle-oriented. Trust in AI is not granted; it is engineered. And pharma, frankly, is culturally better equipped for this than almost any other industry.
